“Embedded in Lupin is a formula for growth which fuels creativity, performance and innovation”
It was Dr. Desh Bandhu Gupta’s vision and passion which helped him grow a small dream into a large company with a global footprint.
The most advanced pharmaceutical product development
Developing new chemical entities for focused therapy areas
Producing quality medicines in areas of
Producing high quality affordable
and accessible biologics
Mumbai, November 05, 2015: Pharma major Lupin Limited today announced the appointment of Thierry Volle
as President of Europe, Middle-East & Africa (EMEA). At Lupin, Thierry will be responsible for the Company's
growth and development in Europe, Russia & CIS, and Middle-east and African markets. He will be based at
Lupin's European headquarters in Zug, Switzerland.
Thierry joins Lupin from Vifor Pharma where he was the head of EU & International business operations. Prior to
that, he was at Wyeth and worked his way through multiple roles of increasing responsibility in Europe as well
as the corporate headquarters in St. Davids, PA. Thierry has extensive international experience in building and
growing specialty pharmaceuticals businesses across markets specifically in EMEA, with a focus on business &
market development, integration & change management and product portfolio management. He holds a
Business diploma from Institut Superieur de Gestion and a Master's degree in Computer Science from Centre
d'etudes superieures industrielles- Centrale, Paris and has also completed various Executive Programs at the
Harvard School of Public Health ,INSEAD and EPFL to name a few.
Commenting on the appointment Vinita Gupta, Chief Executive Officer, Lupin Limited said, "We are delighted to
have Thierry join the Lupin family. His rich knowledge and experience in developing and growing businesses,
specifically specialty pharmaceuticals in EMEA, will help us with our strategic expansion plans for these
About Lupin Limited
Headquartered in Mumbai, Lupin is an innovation led transnational pharmaceutical company producing and
developing a wide range of branded & generic formulations, biotechnology products and APIs globally. The
Company is a significant player in the Cardiovascular, Diabetology, Asthma, Pediatric, CNS, GI, Anti-Infective and
NSAID space and holds global leadership positions in the Anti-TB and Cephalosporin segment.
Lupin is the 6th largest and fastest growing top 10 generics player in the US (5.5% market share by prescriptions,
IMS Health) and the 3rd largest Indian pharmaceutical company by sales globally. The Company is also the fastest
growing top 10 generic pharmaceutical players in Japan (ranked 8th) and South Africa (ranked 4th - IMS Health).
For the financial year ended 31st March 2015, Lupin's Consolidated turnover and Profit after Tax were .
125,997 million (USD 2.06 billion) and . 24,032 million (USD 393 million) respectively.
Please visit http://www.lupin.com for more information.
You could also follow us on Twitter - www.twitter.com/lupinlimited
CIN: L24100MH1983PLC029442 Registered Office: 159, C.S.T. Road, Kalina, Santacruz (East), Mumbai - 400 098
For more information, please contact -
Head - Corporate Communications
Ph: +91-22- 98 20 338 555
Head - M & A and Investor Relations
Ph: +91 98 20 023 511
Safe Harbor Statement